|
|
The 3rd World Congress on
Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Hilton Hotel, Prague, Czech Republic, May 13-16, 2010 |
|
| |
| Friday, May 14, 2010 |
 |
|
|
HALL A |
|
08:30-10:00 |
Plenary Session 1
OUTCOME STUDIES IN THE TREATMENT OF TYPE 2 DIABETES (T2D)
Chairpersons: S. Del Prato, Italy I. Raz, Israel |
|
|
Cellular mechanisms of insulin resistance: Implications for obesity, lipodystrophy, T2D and the metabolic syndrome
G.I. Shulman, USA
What can be learnt from the new ACCORD sub-analysis?
H. Ginsberg, USA
Need for outcome studies in diabetic drug development
|
|
10:30-12:30 |
Session 2
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS: A CLINICAL COMPARISON |
|
|
Impact of glycaemic control impact on body weight potential to reduce cardiovascular (CV) risk
GLP-1: G. Sesti, Italy
DPP-4: I. Raz, Israel
Beta-cell protection
Animal studies: M. Donath, Switzerland
Human perspective: E. Ferrannini, Italy
|
|
14:00-16:00 |
Session 6
THERAPY IN THE EARLY STAGE
Chairperson: J. Meigs, USA |
|
Pharmacologic prevention of T2DM
Pro: R.A. DeFronzo, USA
Con: J. Tuomilehto, Finland
Metformin failure: What is next?
Incretins: S. Del Prato, Italy
Others: G.B. Bolli, Italy
|
|
16:30-18:30
|
Session 9
T2D IN CHILDHOOD |
|
Epidemiology and pathophysiology
S. Caprio, USA
Metabolic syndrome in pediatrics
R. Weiss, Israel
The accelerator hypothesis and the double diabetes
P. Pozzilli, Italy
Treatment of T2D in youth: What's on the horizon?
S. Arslanian, USA
|
|
HALL B |
|
10:30-12:30 |
Session 3
OPTIMAL BLOOD PRESSURE CONTROL |
|
The blood pressure legacy
Pro: L. Ruilope, Spain
Con: G. Parati, Italy
Blood pressure: The lower, the better
Pro: G. Mancia, Italy
Con: A. Zanchetti, Italy
|
|
14:00-16:00 |
Session 7
HYPERTENSION TREATMENT |
|
Angiotensin-converting enzyme (ACE) inhibition and CV protection. The role of metabolic profile
G. Viberti, UK
Diuretic treatment of hypertension
Pro: E. Grossman, Israel
Con: P. Verdecchia, Italy
|
|
16:30-18:30
|
Session 10
RENIN-ANGIOTENSIN SYSTEM (RAS) AND COMPLICATIONS |
|
Epidermal growth factor receptor (eGFR) or albuminuria as predictors for renal and CV outcome
eGFR: M. Ravid, Israel
Albuminuria: D. de Zeeuw, Netherlands
RAS blockade for every diabetic
Pro:
Con: A. Solini, Italy
|
|
HALL C |
|
10:30-12:30
|
Session 4
OBESITY: CAUSE AND DIFFERENT APPROACHES |
|
Socioeconomic/depression as common soil for obesity
Should obesity be treated at any age?
R. Bonadonna, Italy
Physical exercise. How and how much?
P. de Feo, Italy
Effective diet for weight loss
|
|
14:00-16:00
|
Session 8
GLUCOSE VARIABILITY
Chairpersons: E. Ferrannini, Italy M. Petkova, Bulgaria |
|
Postprandial glucose and glucose variability. Should we care?
Pro: A. Ceriello, UK
Con: E. Standl, Germany
Continuous glucose monitoring (closing the loop)
Expectations: M. Philip, Israel
Doubts: J.H. de Vries, Netherlands
|
|
16:30-18:30 |
Session 11
BLOOD VESSELS, ENDOTHELIUM AND METABOLIC DISEASES
Chairperson: C. Stehouwer, Netherlands |
|
Inflammation
J.M. Real-Fernandez, Spain
The role of metalloproteinases. At the interface between metabolic and inflammatory disorders
M. Federici, Italy
Vascular disease in diabetes. The role of reparatory mechanisms
A. Avogaro, Italy
Endothelial factors and diabetic nephropathy
L. Gnudi, UK
|
|
|
|
|
WebStudio.co.il